Sacha Gnjatic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/308035/publications.pdf

Version: 2024-02-01

238	28,421	11608	6113
papers	citations	70 h-index	159 g-index

269	269	269	37996
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	3.3	2,100
2	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	15.2	1,860
3	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 925-931.	13.9	1,836
4	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell, 2017, 169, 750-765.e17.	13.5	937
5	Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity, 2016, 44, 924-938.	6.6	857
6	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
7	Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. New England Journal of Medicine, 2008, 358, 2698-2703.	13.9	834
8	Tumor-infiltrating NY-ESO-1â€“specific CD8 ⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7875-7880.	3.3	744
9	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
10	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
11	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nature Medicine, 2018, 24, 1845-1851.	15.2	626
12	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 832-844.	2.5	564
13	Single-cell immune landscape of human atherosclerotic plaques. Nature Medicine, 2019, 25, 1576-1588.	15.2	540
14	Single-Cell Analysis of Crohnâ€™s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell, 2019, 178, 1493-1508.e20.	13.5	519
15	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3967-3972.	3.3	445
16	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 2020, 183, 982-995.e14.	13.5	440
17	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10697-10702.	3.3	411
18	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395

#	Article	IF	Citations
19	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. Cancer Research, 2011, 71, 5670-5677.	0.4	369
20	The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response. International Journal of Radiation Oncology Biology Physics, 2013, 85, 293-295.	0.4	360
21	CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Research, 2009, 37, D816-D819.	6.5	338
22	Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 8055-8062.	3.2	325
23	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20410-20415.	3.3	322
24	NYâ€ESOâ€1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	1.9	311
25	Integrated NY-ESO-1 antibody and CD8⁺T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16723-16728.	3.3	310
26	Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients. Clinical Cancer Research, 2012, 18, 6497-6508.	3.2	245
27	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12837-12842.	3.3	239
28	Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant. Journal of Immunology, 2008, 181, 776-784.	0.4	230
29	The Nonâ€“Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 377-390.	2.5	204
30	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14453-14458.	3.3	202
31	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood, 2008, 111, 1357-1365.	0.6	202
32	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101â€“0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1â€“Expressing Melanoma. Journal of Experimental Medicine, 2000, 191, 625-630.	4.2	196
33	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Research, 2003, 63, 6076-83.	0.4	191
34	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clinical Infectious Diseases, 2020, 71, 2933-2938.	2.9	189
35	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Modern Pathology, 2021, 34, 1456-1467.	2.9	184
36	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181

#	Article	IF	Citations
37	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8862-8867.	3.3	179
38	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. Journal of Immunology, 2004, 172, 3289-3296.	0.4	176
39	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5797-5802.	3.3	173
40	Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer. Cancer Immunology Research, 2014, 2, 37-49.	1.6	168
41	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	3.9	164
42	Seromic profiling of ovarian and pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5088-5093.	3.3	163
43	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. Journal of Immunology, 2000, 165, 948-955.	0.4	161
44	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood, 2005, 106, 1008-1011.	0.6	160
45	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood, 2007, 109, 1103-1112.	0.6	154
46	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma, 2013, 2013, 1-8.	0.7	151
47	Host tissue determinants of tumour immunity. Nature Reviews Cancer, 2019, 19, 215-227.	12.8	150
48	Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1650-1655.	3.3	149
49	Toll-Like Receptor Agonists. Cancer Journal (Sudbury, Mass), 2010, 16, 382-391.	1.0	144
50	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology, 2016, 1, aaf6925.	5.6	142
51	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	1.9	140
52	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
53	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Frontiers in Immunology, 2015, 6, 67.	2.2	122
54	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119

#	Article	IF	Citations
55	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	0.6	118
56	Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma. Journal of Immunotherapy, 2012, 35, 89-97.	1.2	115
57	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunology Research, 2013, 1, 235-244.	1.6	109
58	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. Journal of Hematology and Oncology, 2020, 13, 94.	6.9	107
59	Tumorâ€reactive CD8⁺ Tâ€cell responses after vaccination with NYâ€ESOâ€1 peptide, CpG 7909 and MontanideÂ® ISAâ€51: association with survival. International Journal of Cancer, 2010, 126, 909-918.	2.3	103
60	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology, 2021, 161, 715-718.e4.	0.6	102
61	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology, 2018, 73, 751-759.	0.9	99
62	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clinical Cancer Research, 2008, 14, 2740-2748.	3.2	98
63	Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity. Journal of Immunology, 2011, 186, 1218-1227.	0.4	98
64	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. European Radiology, 2020, 30, 3759-3769.	2.3	97
65	NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors. Cancer Research, 2004, 64, 2199-2204.	0.4	92
66	Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer. Cancer Research, 2014, 74, 7205-7216.	0.4	87
67	NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer. PLoS ONE, 2012, 7, e38783.	1.1	85
68	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11813-11818.	3.3	83
69	Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. Cancer Immunology Research, 2015, 3, 278-287.	1.6	81
70	Regulatory T Cellâ€“Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research, 2008, 68, 5948-5954.	0.4	80
71	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	3.7	79
72	Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell, 2022, 185, 1223-1239.e20.	13.5	79

#	Article	IF	Citations
73	Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10629-10634.	3.3	78
74	NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. Clinical Cancer Research, 2009, 15, 2130-2139.	3.2	74
75	Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. Journal of Immunological Methods, 2009, 341, 50-58.	0.6	71
76	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immunity, 2007, 7, 11.	3.2	71
77	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine, 2022, 14, eabm7853.	5.8	71
78	Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity. Clinical Cancer Research, 2012, 18, 5449-5459.	3.2	70
79	Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Scientific Reports, 2015, 5, 14896.	1.6	70
80	Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Scientific Reports, 2017, 7, 2452.	1.6	70
81	Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. Journal of Clinical Investigation, 2002, 110, 1813-1822.	3.9	70
82	Dissecting cytotoxic Tâ€„cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. European Journal of Immunology, 2004, 34, 2919-2929.	1.6	67
83	Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein. Clinical Cancer Research, 2013, 19, 6112-6125.	3.2	66
84	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research, 2019, 25, 5808-5817.	3.2	66
85	The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients. Clinical Cancer Research, 2004, 10, 6946-6955.	3.2	65
86	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood, 2012, 119, 3097-3104.	0.6	65
87	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e104099.	1.1	65
88	NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer. Clinical Cancer Research, 2004, 10, 6551-6558.	3.2	62
89	Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial. Cancer Immunology Research, 2013, 1, 340-350.	1.6	62
90	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 450-464.	3.2	62

#	Article	IF	Citations
91	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	7.7	62
92	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 420-425.	0.6	61
93	Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination. Journal of Immunology, 2006, 176, 6340-6346.	0.4	52
94	NYâ€COâ€58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. International Journal of Cancer, 2010, 127, 381-393.	2.3	52
95	Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF. Journal of Immunotherapy, 2008, 31, 849-857.	1.2	51
96	Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. Clinical Cancer Research, 2010, 16, 3562-3570.	3.2	51
97	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Gastroenterology, 2016, 151, 710-723.e2.	0.6	51
98	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. Journal of Immunotherapy, 2017, 40, 302-306.	1.2	51
99	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2470-2480.	3.2	51
100	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immunity, 2007, 7, 18.	3.2	51
101	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. Journal of Immunology, 2003, 170, 1191-1196.	0.4	50
102	Trypanosoma cruzias an effective cancer antigen delivery vector. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19695-19700.	3.3	48
103	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunology Research, 2020, 8, 70-80.	1.6	47
104	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. Journal of Immunological Methods, 2003, 278, 57-66.	0.6	46
105	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.4	46
106	<scp>NYâ€ESO</scp>â€1 specific antibody and cellular responses in melanoma patients primed with <scp>NYâ€ESO</scp>â€1 protein in <scp>ISCOMATRIX</scp> and boosted with recombinant <scp>NYâ€ESO</scp>â€1 fowlpox virus. International Journal of Cancer, 2015, 136, E590-601.	2.3	46
107	Autoantibodies Against Cancer Antigens. Methods in Molecular Biology, 2009, 520, 11-19.	0.4	45
108	In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15â€"Binding CD4 T-Cell Epitope. Clinical Cancer Research, 2006, 12, 1921-1927.	3.2	44

#	Article	IF	Citations
109	Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer. Journal of Immunotherapy, 2012, 35, 513-521.	1.2	42
110	Myeloid Cellâ€“associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical Cancer Research, 2021, 27, 4287-4300.	3.2	42
111	Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nature Communications, 2021, 12, 4854.	5.8	42
112	Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. Oncotarget, 2019, 10, 7142-7155.	0.8	42
113	Nonclassical Antigen-Processing Pathways Are Required for MHC Class IIâ€“Restricted Direct Tumor Recognition by NY-ESO-1â€“Specific CD4+ T Cells. Cancer Immunology Research, 2014, 2, 341-350.	1.6	41
114	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immunity, 2007, 7, 16.	3.2	41
115	Heteroclitic serological response in esophageal and prostate cancer patients after NYâ€ESOâ€1 protein vaccination. International Journal of Cancer, 2012, 130, 584-592.	2.3	38
116	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	15.2	38
117	Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma. Journal of Immunotherapy, 2007, 30, 847-854.	1.2	37
118	IFN-Â enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14467-14472.	3.3	36
119	Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immunity, 2003, 3, 19.	3.2	36
120	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3093-3098.	3.3	35
121	Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells. Journal of Immunology, 2012, 188, 3851-3858.	0.4	35
122	Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS): Multiplexed Chromogenic IHC Assay for High-Dimensional Tissue Analysis. Methods in Molecular Biology, 2020, 2055, 497-519.	0.4	35
123	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immunity, 2010, 10, 4.	3.2	35
124	Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. European Journal of Immunology, 1995, 25, 1638-1642.	1.6	34
125	Characterization of Preexisting MAGE-A3-Specific CD4+ T Cells in Cancer Patients and Healthy Individuals and Their Activation by Protein Vaccination. Journal of Immunology, 2009, 183, 4800-4808.	0.4	33
126	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity, 2010, 10, 1.	3.2	32

#	Article	IF	Citations
127	MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immunity, 2012, 12, 16.	3.2	32
128	Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content. Journal of Clinical Immunology, 2006, 26, 447-456.	2.0	31
129	Immunohistochemical Detection of Î³Î´ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 581-583.	0.6	31
130	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology, 2022, 40, 1680-1689.	9.4	29
131	Induction of regulatory T cellâ€“resistant helper CD4+ T cells by bacterial vector. Blood, 2008, 111, 1404-1412.	0.6	28
132	A streamlined whole blood <scp>CyTOF</scp> workflow defines a circulating immune cell signature of <scp>COVID</scp>â€19. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 446-461.	1.1	28
133	NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immunity, 2003, 3, 10.	3.2	28
134	Sampling the host response to SARS-CoV-2 in hospitals under siege. Nature Medicine, 2020, 26, 1157-1158.	15.2	27
135	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. International Journal of Cancer, 2007, 121, 2042-2048.	2.3	25
136	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood, 2021, 137, 3212-3217.	0.6	24
137	Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immunity, 2004, 4, 11.	3.2	24
138	Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunology, Immunotherapy, 2008, 57, 1185-1195.	2.0	22
139	First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunology, Immunotherapy, 2019, 68, 1211-1222.	2.0	22
140	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. OncoImmunology, 2020, 9, 1847846.	2.1	22
141	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
142	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 2016, 34, 357-357.	0.8	21
143	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	0.8	21
144	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freundâ€™s adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20

#	Article	IF	Citations
145	Therapeutic Administration of a Synthetic CpG Oligodeoxynucleotide Triggers Formation of Anti-CpG Antibodies. Cancer Research, 2012, 72, 4304-4310.	0.4	19
146	Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immunity, 2004, 4, 12.	3.2	19
147	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunology, Immunotherapy, 2015, 64, 1193-1203.	2.0	18
148	A multimodal imaging workflow to visualize metal mixtures in the human placenta and explore colocalization with biological response markers. Metallomics, 2016, 8, 444-452.	1.0	18
149	Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohnâ€™s Disease. Gastroenterology, 2022, 163, 659-670.	0.6	18
150	Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages. Aids, 2020, 34, 1581-1591.	1.0	17
151	Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles. Journal of Immunotherapy, 2008, 31, 607-619.	1.2	15
152	Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors. PLoS ONE, 2011, 6, e23651.	1.1	15
153	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkinâ€™s lymphoma patients. Cancer Immunology, Immunotherapy, 2012, 61, 2207-2214.	2.0	15
154	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head and Neck, 2016, 38, 1008-1016.	0.9	14
155	Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2017, 35, 11006-11006.	0.8	14
156	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget, 2020, 11, 2669-2683.	0.8	14
157	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immunity, 2002, 2, 12.	3.2	14
158	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
159	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccineâ€“Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunology Research, 2019, 7, 658-669.	1.6	12
160	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nature Medicine, 2022, 28, 626-629.	15.2	12
161	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. International Journal of Cancer, 2006, 118, 668-674.	2.3	11
162	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. Cancer Immunology Research, 2014, 2, 404-409.	1.6	10

#	Article	IF	Citations
163	From local to global. Nature Nanotechnology, 2017, 12, 840-841.	15.6	10
164	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	3.2	10
165	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 2013, 13, 3.	3.2	10
166	Cancerâ€“Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma. Cancer Immunology Research, 2014, 2, 547-558.	1.6	9
167	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
168	Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immunity, 2011, 11, 1.	3.2	9
169	Overcoming regulatory Tâ€cell suppression by a lyophilized preparation of Streptococcus pyogenes. European Journal of Immunology, 2013, 43, 989-1000.	1.6	8
170	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. American Journal of Dermatopathology, 2016, 38, 201-207.	0.3	8
171	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecologic Oncology, 2016, 142, 158-162.	0.6	8
172	Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study. Journal of Physical Education and Sports Management, 2020, 6, a004762.	0.5	8
173	A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8. AACE Clinical Case Reports, 2020, 6, e151-e160.	0.4	8
174	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	3.2	8
175	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. Journal of Clinical Oncology, 2015, 33, 3021-3021.	0.8	8
176	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume Iâ€”conceptual challenges. , 2020, 8, e001389.		7
177	Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM). Blood, 2014, 124, 1184-1184.	0.6	7
178	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 300-300.	0.8	7
179	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. Translational Lung Cancer Research, 2021, 10, 3079-3092.	1.3	6
180	Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy. OncoImmunology, 2012, 1, 405-407.	2.1	5

#	Article	IF	Citations
181	Antigen depots: T cell traps?. Nature Medicine, 2013, 19, 397-398.	15.2	5
182	A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. Journal of Clinical Oncology, 2018, 36, 5553-5553.	0.8	5
183	HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Cancer Immunity, 2004, 4, 15.	3.2	5
184	400 GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF CROHN'S DISEASE AND PREDICT COMPLICATED PHENOTYPE AT DIAGNOSIS. Gastroenterology, 2020, 158, S-74.	0.6	4
185	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume IIâ€"practical challenges. , 2020, 8, e001472.		4
186	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2015, 33, 4586-4586.	0.8	4
187	Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.. Journal of Clinical Oncology, 2017, 35, 3090-3090.	0.8	4
188	A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. Journal of Clinical Oncology, 2017, 35, TPS3114-TPS3114.	0.8	4
189	Immunogenic Targets in Nonâ€"Small Cell Lung Cancer: More Is More. Clinical Cancer Research, 2005, 11, 5331-5332.	3.2	3
190	Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma. Cancer Research, 2021, 81, CT182-CT182.	0.4	3
191	A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1.. Journal of Clinical Oncology, 2015, 33, 3073-3073.	0.8	3
192	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. Journal of Clinical Oncology, 2016, 34, 3093-3093.	0.8	3
193	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. Journal of Clinical Oncology, 2019, 37, 9538-9538.	0.8	3
194	Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, TPS2074-TPS2074.	0.8	3
195	High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 853-862.	0.2	3
196	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunology, Immunotherapy, 2013, 62, 1327-1334.	2.0	2
197	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects. OncoImmunology, 2014, 3, e27580.	2.1	2
198	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.. Journal of Clinical Oncology, 2018, 36, e15171-e15171.	0.8	2

#	Article	IF	Citations
199	CTIM-09. PHASE I STUDY OF PD-L1 INHIBITION WITH AVELUMAB AND LASER INTERSTITIAL THERMAL THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi51.	0.6	2
200	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2020, 136, 28-29.	0.6	2
201	Abstract CT108: Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to MontanideÂ® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence. Cancer Research, 2022, 82, CT108-CT108.	0.4	2
202	Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients. Journal of Immunotherapy, 2005, 28, 659.	1.2	1
203	Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Cancer Research, 2021, 81, LB048-LB048.	0.4	1
204	Abstract 5639: Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer. , 2018, , .		1
205	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. Blood, 2006, 108, 3492-3492.	0.6	1
206	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, TPS9119-TPS9119.	0.8	1
207	Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.. Journal of Clinical Oncology, 2015, 33, TPS6088-TPS6088.	0.8	1
208	CIMAC-CIDC tissue imaging harmonization.. Journal of Clinical Oncology, 2020, 38, 3125-3125.	0.8	1
209	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, 9086-9086.	0.8	1
210	A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.. Journal of Clinical Oncology, 2020, 38, TPS9638-TPS9638.	0.8	1
211	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 6551-6551.	0.8	1
212	CIMAC-CIDC CyTOF harmonization.. Journal of Clinical Oncology, 2020, 38, e15242-e15242.	0.8	1
213	Abstract CT231: Clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma. Cancer Research, 2020, 80, CT231-CT231.	0.4	1
214	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. Blood, 2020, 136, 17-18.	0.6	1
215	A multiplexed immunohistochemical consecutive staining on single slide (MICSSS) analysis of the immune microenvironment of bile duct cancers (BDC) pre and post neoadjuvantchemotherapy (NACT).. Journal of Clinical Oncology, 2022, 40, e16151-e16151.	0.8	1
216	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€, Napoli, December 5th 2015. , 2016, 4, .		0

#	Article	IF	Citations
217	NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 30.	0.6	0
218	Phase II Evaluation of an Allogeneic Tumor Cell Lysate Vaccine with or without Metronomic Oral Cyclophosphamide and Celecoxib in Patients with Thoracic Malignancies. Journal of the American College of Surgeons, 2017, 225, e10.	0.2	0
219	IMMU-60. MAPPING TUMORAL AND IMMUNE HETEROGENEITY IN PD-1 RESPONSIVE GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi135-vi135.	0.6	0
220	Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS. Gastroenterology, 2021, 160, S-330.	0.6	0
221	Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.. Journal of Clinical Oncology, 2015, 33, e14034-e14034.	0.8	0
222	Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5546-5546.	0.8	0
223	Abstract 1318: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma multiforme. , 2018, , .		0
224	Abstract IA34: Mapping immune recognition of non-self neoantigens in human pancreatic cancer. , 2019, , .		0
225	Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. , 2019, , .		0
226	Abstract IA31: Measuring the emergence of non-self in tumors. , 2019, , .		0
227	Abstract B088: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma. , 2019, , .		0
228	Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy. Blood, 2019, 134, 3093-3093.	0.6	0
229	Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma. Blood, 2019, 134, 4367-4367.	0.6	0
230	High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment. Blood, 2019, 134, 4384-4384.	0.6	0
231	Abstract 3381: Identifying tumor antigen-specific CD4+ T cell dysfunctional states by single cell transcriptomics in immunotherapy-treated cancer patients. , 2020, , .		0
232	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2021, 138, 2691-2691.	0.6	0
233	510. Elevated IL-1Î² level as a predictor of inflammation and death in COVID-19. Open Forum Infectious Diseases, 2020, 7, S320-S321.	0.4	0
234	289â€…PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0

#	Article	IF	Citations
235	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. Blood, 2020, 136, 15-15.	0.6	0
236	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. Blood, 2020, 136, 6-8.	0.6	0
237	Abstract 2528: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma. , 2019, , .		0
238	Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab Â± ipilimumab.. Journal of Clinical Oncology, 2022, 40, 9044-9044.	0.8	0